Drug intelligence / Profile preview

CAM-5746

Development stage: Preclinical
Lead developer: Cambrian Bio
Modality: Small Molecules

Overview

CAM-5746 is a preclinical-stage drug candidate being developed by Cambrian Bio (through a stealth subsidiary) to address the loss of proteostasis, one of the hallmarks of aging. Proteostasis involves the maintenance of the proteome's integrity through protein folding, trafficking, and degradation. Dysregulation of these pathways is linked to various pathologies, including protein misfolding diseases. CAM-5746 is specifically being investigated for the treatment of autoimmune and rare diseases. As of 2024, the program is in the lead optimization stage of preclinical development.

Beyond the preview

Go deeper on CAM-5746.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAM-5746.

Explore the full profile